<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63828">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01949337</url>
  </required_header>
  <id_info>
    <org_study_id>A031201</org_study_id>
    <secondary_id>U10CA031946</secondary_id>
    <secondary_id>NCI-2013-01737</secondary_id>
    <nct_id>NCT01949337</nct_id>
  </id_info>
  <brief_title>Enzalutamide With or Without Abiraterone Acetate and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer</brief_title>
  <official_title>Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Astellas Pharma US, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medivation, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biologics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: NCI Central Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase III trial studies enzalutamide to see how well it works compared to
      enzalutamide, abiraterone acetate, and prednisone in treating patients with
      castration-resistant metastatic prostate cancer. Androgens can cause the growth of prostate
      cancer cells. Drugs, such as enzalutamide, abiraterone acetate, and prednisone, may lessen
      the amount of androgens made by the body.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomized to one of two treatment groups: enzalutamide or enzalutamide,
      abiraterone and prednisone. Treatment will continue until disease progression or
      unacceptable toxicity.  Patients are followed for clinical outcomes for a maximum of 5 years
      post study treatment. The primary and secondary objectives are described below.

        1. Primary Objective:

           To compare the overall survival of patients with progressive metastatic
           castration-resistant prostate cancer (CRPC) treated with either enzalutamide only or
           enzalutamide with abiraterone (abiraterone acetate) and prednisone

        2. Secondary Objectives:

             -  To assess the grade 3 or higher toxicity profile and compare safety by treatment
                arm.

             -  To assess and compare post-treatment prostate-specific antigen (PSA) declines by
                treatment arm.

             -  To compare radiographic progression free survival defined by Prostate Cancer
                Working Group 2 (PCWG2), and objective response rate, by treatment arm.

             -  To test for radiographic progression free survival (rPFS) treatment interaction in
                predicting overall survival.

             -  To assess pre- and post-treatment measures of tumor burden and bone activity using
                sodium fluoride (NaF) positron emission tomography (PET)/computed tomography (CT)
                and technetium (Tc) methylene diphosphonate (MDP) bone scintigraphy and correlate
                these measures with overall survival.

             -  To develop and validate prognostic and predictive models of overall survival that
                include baseline clinical and molecular markers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 5 years post treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grade 3 or higher toxicity profile using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</measure>
    <time_frame>Up to 5 years post treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decline in Prostate Specific Antigen (PSA)</measure>
    <time_frame>Up to 5 years post treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 5 years post treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to 5 years post treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic Progression Free Survival (rPFS)</measure>
    <time_frame>Up to 5 years post treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor burden and bone activity</measure>
    <time_frame>Up to 5 years post treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1224</enrollment>
  <condition>Adenocarcinoma of the Prostate</condition>
  <condition>Hormone-resistant Prostate Cancer</condition>
  <condition>Recurrent Prostate Cancer</condition>
  <condition>Stage IV Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: (enzalutamide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive enzalutamide 160 mg PO QD. Treatment will continue until confirmed disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: (enzalutamide, abiraterone acetate, prednisone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive enzalutamide 160 mg PO QD, abiraterone acetate 1000 mg PO QD, and prednisone 5 mg PO BID.  Treatment will continue until confirmed disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enzalutamide</intervention_name>
    <description>Enzalutamide  160 mg daily, orally</description>
    <arm_group_label>Arm A: (enzalutamide)</arm_group_label>
    <arm_group_label>Arm B: (enzalutamide, abiraterone acetate, prednisone)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abiraterone</intervention_name>
    <description>abiraterone  1000 mg daily, orally</description>
    <arm_group_label>Arm B: (enzalutamide, abiraterone acetate, prednisone)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>prednisone 5 mg twice daily, orally</description>
    <arm_group_label>Arm B: (enzalutamide, abiraterone acetate, prednisone)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility Criteria:

          1. Documentation of Disease - Progressive castration-resistant metastatic prostate
             cancer with histologically or cytologically confirmed adenocarcinoma of the prostate
             without neuroendocrine differentiation or small cell features

          2. Patients must have measurable or non-measurable disease:

               1. Measurable Disease - For visceral or extra nodal lesions to be considered
                  measurable, they must be ≥ 10 mm in one dimension, using spiral CT.  For lymph
                  nodes to be considered measurable (ie, target or evaluable lesions), they must
                  be ≥ 20 mm in at least one dimension, using spiral CT.

               2. Non-Measurable Disease - All other lesions, including small lesions (longest
                  diameter &lt; 20 mm with conventional techniques or &lt; 10 mm with spiral CT scan)
                  and truly non-measurable lesions. Lesions that are considered non-measurable
                  include bone lesions (only).

          3. Progressive Disease - Patients must have progressive disease at study entry defined
             as one or more of the following three criteria that occurred while the patient was on
             androgen deprivation therapy. For patients enrolling on the basis of soft tissue or
             bone progression, the baseline scan must show progression relative to a comparison
             scan. If the comparison scan is not available, the baseline scan report must
             reference the previous scan to document progression.

               1. PSA progression defined by a minimum of two rising PSA levels with an interval
                  of ≥ 1 week between each determination. Patients who received an anti-androgen
                  must have progression documented by a minimum of two rising PSA levels with an
                  interval of ≥ 1 week between each determination such that at least the second of
                  these rises is ≥ 4 weeks since last flutamide or ≥ 6 weeks since last
                  bicalutamide or nilutamide. The PSA value at the screening should be ≥ 2 µg/L (2
                  ng/mL) 

               2. Soft tissue disease progression defined by the protocol

               3. Bone disease progression defined by the Prostate Cancer Working Group 2 (PCWG2)
                  with two or more new lesions on bone scan

          4. Prior Treatment

               1. No treatment with prior taxane-based chemotherapy for metastatic disease 

                    -  Patients who received prior taxane-based chemotherapy as neoadjuvant or
                       adjuvant therapy for local disease, or who received taxane-based therapy in
                       the PSA clinical (non-metastatic) state is allowable provided that the
                       total duration of exposure was six cycles or less and chemotherapy was
                       completed more than 6 months prior to registration 

                    -  Taxane-based chemotherapy that was aborted due to allergic reactions or
                       intolerance to chemotherapy and therefore received one cycle of prior
                       therapy is allowable

               2. No prior enzalutamide, abiraterone or other novel antiandrogen or androgen
                  synthesis inhibitor

               3. No treatment with any of the following for prostate cancer within 4 weeks prior
                  to enrollment:

                    -  Hormonal therapy (e.g., androgen receptor [AR] antagonists, 5 alpha
                       reductase inhibitors, estrogens) Note: Treatment with bicalutamide and
                       nilutamide within 6 weeks prior to enrollment is not allowed. Treatment
                       with flutamide within 4 weeks prior to enrollment is not allowed. Treatment
                       with all other gonadotropin-releasing hormone (GnRH) analogues or
                       antagonists is allowed.

                    -  Chemotherapy

                    -  Biologic therapy

                    -  Investigational therapy

                    -  Immunotherapy

               4. No use of herbal products that may decrease PSA levels within 4 weeks prior to
                  enrollment

               5. No use of systemic steroids greater than the equivalent of 10 mg of
                  prednisone/prednisolone per day within 4 weeks prior to enrollment

               6. No prior use of ketoconazole for greater than 7 days

               7. No prior radiation therapy or radionuclide therapy for the treatment of
                  metastasis within four weeks prior to enrollment

               8. Patients receiving bisphosphonate therapy or denosumab must have been on a
                  stable dose for at least 4 weeks prior to enrollment

               9. Patients must maintain ongoing androgen deprivation therapy with a GnRH
                  analogue, antagonist, or bilateral orchiectomy (i.e., surgical or medical
                  castration)

          5. Patient History

               1. No known or suspected brain metastases (NOTE: patients with treated epidural
                  disease are allowed)

               2. No planned palliative procedures for alleviation of bone pain such as radiation
                  therapy or surgery

               3. No structurally unstable bone lesions suggesting impending fracture

               4. No history of seizure or any condition that may increase the patient's seizure
                  risk (e.g., prior cortical stroke, significant brain trauma). No history of
                  transient ischemic attack (TIA) within 12 months of enrollment

               5. No clinically significant cardiovascular disease including: 

                    -  Myocardial infarction (MI) within 6 months 

                    -  Uncontrolled angina within 3 months 

                    -  Congestive heart failure (CHF) with New York Heart Association (NYHA) class
                       3 or 4, or patients with NYHA class 3 or 4 in the past, unless a screening
                       echocardiogram (echo) or multigated acquisition scan (MUGA) performed
                       within three months demonstrates an ejection fraction (EF) &gt; 45% 

                    -  History of clinically significant ventricular arrhythmias (e.g.,
                       ventricular tachycardia, ventricular fibrillation, torsades de pointes) 

                    -  History of Mobitz II second degree or third degree heart block without a
                       permanent pacemaker in place 

                    -  Hypotension (systolic blood pressure [BP] &lt; 86 mmHg) or bradycardia (&lt; 50
                       bpm) at screening  

                    -  Uncontrolled hypertension (systolic BP &gt; 170 mmHg or diastolic BP &gt; 105
                       mmHg at screening)

               6. No gastrointestinal (GI) disorder that negatively affects absorption

               7. No major surgery within 4 weeks prior to enrollment

          6. Age and performance status

               1. Age ≥ 18 years of age

               2. Eastern Cooperative Oncology Group (ECOG) performance status 0-1

               3. Asymptomatic or mildly symptomatic from prostate cancer

          7. Required Initial Laboratory Values

               1. Granulocytes ≥ 1,500/µL

               2. Platelet count ≥ 100,000/µL

               3. Hemoglobin ≥ 9 g/dL

               4. Creatinine ≤ 2 x upper limits of normal (ULN)

               5. Bilirubin   ≥ 1.5 x ULN

               6. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2 x ULN

               7. Albumin ≥ 3 g/dl

               8. Serum testosterone ≤ 50 ng/dL (1.7 nmol/L)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Morris, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan-Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Randall, M.D.</last_name>
      <phone>858-822-6185</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSF - Mount Zion</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terence Friedlander, M.D.</last_name>
      <phone>415-514-8481</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Shaw Regional Cancer Center</name>
      <address>
        <city>Edwards</city>
        <state>Colorado</state>
        <zip>81632</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Urquhart, M.D.</last_name>
      <phone>970-569-7684</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Francis Hospital and Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Stella, M.D.</last_name>
      <phone>734-712-4931</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center CCOP</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Schwartz, M.D.</last_name>
      <phone>305-674-2625</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sacred Heart Medical Oncology Group - Davis Highway</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Watkins, M.D.</last_name>
      <phone>850-416-6933</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sacred Heart Hospital</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Watkins, M.D.</last_name>
      <phone>850-416-6933</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Care - Peoria</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nguyet Le-Lindqwister, M.D.</last_name>
      <phone>309-672-5681</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quincy Medical Group - Clinic</name>
      <address>
        <city>Quincy</city>
        <state>Illinois</state>
        <zip>62301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond Smith, M.D.</last_name>
      <phone>217-277-3500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Michiana Hematology Oncology PC-Mishawaka</name>
      <address>
        <city>Mishawaka</city>
        <state>Indiana</state>
        <zip>46545</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Zon, M.D.</last_name>
      <phone>574-647-6343</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Michiana Hematology Oncology-PC Westville</name>
      <address>
        <city>Westville</city>
        <state>Indiana</state>
        <zip>46391</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Zon</last_name>
      <phone>574-647-6343</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates - Quad Cities</name>
      <address>
        <city>Bettendorf</city>
        <state>Iowa</state>
        <zip>52722</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shobha Chitneni, M.D.</last_name>
      <phone>563-355-7733</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Genesis Medical Center - East Campus</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <zip>52803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Kovach, M.D.</last_name>
      <phone>563-421-1960</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Vaena, M.D.</last_name>
      <phone>319-356-3944</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA Medical Center - University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Vaena, M.D.</last_name>
      <phone>319-356-3944</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harold Alfond Center for Cancer Care</name>
      <address>
        <city>Augusta</city>
        <state>Maine</state>
        <zip>04330</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas H. Openshaw</last_name>
      <phone>207-621-6100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eastern Maine Medical Center</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Openshaw, M.D.</last_name>
      <phone>207-973-7474</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Frederick Memorial Hospital</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elhamy Eskander, M.D.</last_name>
      <phone>301-662-8477</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip J. Stella</last_name>
      <phone>734-712-5947</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Chapman, M.D.</last_name>
      <phone>313-916-1784</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Green Bay Oncology - Escanaba</name>
      <address>
        <city>Escanaba</city>
        <state>Michigan</state>
        <zip>49431</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony J. Jaslowski</last_name>
      <phone>610-402-2273</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Green Bay Oncology - Iron Mountain</name>
      <address>
        <city>Iron Mountain</city>
        <state>Michigan</state>
        <zip>49801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony J. Jaslowski</last_name>
      <phone>610-402-2273</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Mary Mercy Hospital</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <zip>48154</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip J. Stella</last_name>
      <phone>610-402-2273</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Mary's of Michigan</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip J. Stella</last_name>
      <phone>610-402-2273</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Anderson, M.D.</last_name>
      <phone>952-993-1517</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Essentia Health Duluth Clinic CCOP</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bret Friday, M.D.</last_name>
      <phone>218-786-3625</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Park Nicollet Cancer Center</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel M. Anderson</last_name>
      <phone>952-993-3248</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Francis Regional Medical Center</name>
      <address>
        <city>Shakopee</city>
        <state>Minnesota</state>
        <zip>55379</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Anderson, M.D.</last_name>
      <phone>952-993-1517</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lakeview Hospital</name>
      <address>
        <city>Stillwater</city>
        <state>Minnesota</state>
        <zip>55082</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel M. Anderson</last_name>
      <phone>651-439-1517</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Francis Medical Center</name>
      <address>
        <city>Cape Giradeau</city>
        <state>Missouri</state>
        <zip>63703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Wade, M.D.</last_name>
      <phone>217 876-6600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Busiek, M.D.</last_name>
      <phone>314-205-6737</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Missouri - Ellis Fischel</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Doll, M.D.</last_name>
      <phone>573-882-6964</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Missouri Baptist Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan P. Lyss</last_name>
      <phone>610-402-2273</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel Picus, M.D.</last_name>
      <phone>314-362-5740</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital - Springfield</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay Carlson, M.D.</last_name>
      <phone>417-820-3554</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Healthcare</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Marchello, M.D.</last_name>
      <phone>406-238-6290</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bozeman Deaconess Cancer Center</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <zip>59715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin T. Marchello, MD</last_name>
      <phone>406-238-6290</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Hauke, M.D.</last_name>
      <phone>402-991-8070</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HealthCare Partners Medical Group Oncology/Hematology-San Martin</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Ellerton, M.D.</last_name>
      <phone>702-822-2000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HealthCare Partners Medical Group Oncology/Hematology-Tenaya</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Ellerton, M.D.</last_name>
      <phone>702-822-2000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Hampshire Oncology - Hematology PA</name>
      <address>
        <city>Concord</city>
        <state>New Hampshire</state>
        <zip>03301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederick Briccetti, M.D.</last_name>
      <phone>603-552-9170</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wentworth Douglass Hospital</name>
      <address>
        <city>Dover</city>
        <state>New Hampshire</state>
        <zip>03820</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taylor Ortiz, M.D.</last_name>
      <phone>603-742-8787</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Hampshire Oncology Hematology Associates</name>
      <address>
        <city>Hooksett</city>
        <state>New Hampshire</state>
        <zip>03106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederick Briccetti, M.D.</last_name>
      <phone>603-552-9170</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>LRGHealthcare-Lakes Region General Hospital</name>
      <address>
        <city>Laconia</city>
        <state>New Hampshire</state>
        <zip>03246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederick Briccetti, M.D.</last_name>
      <phone>603-552-9170</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Lauer, M.D.</last_name>
      <phone>505-925-0478</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Medical Center-Las Cruces</name>
      <address>
        <city>Las Cruces</city>
        <state>New Mexico</state>
        <zip>88011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Lauer, M.D.</last_name>
      <phone>505-925-0478</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christus Saint Vincent Regional Cancer Center</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <zip>87505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Lauer, M.D.</last_name>
      <phone>505-925-0478</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Becker, M.D.</last_name>
      <phone>718-765-2600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael J. Morris</last_name>
      <phone>212-639-2000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Randolph Hospital</name>
      <address>
        <city>Asheboro</city>
        <state>North Carolina</state>
        <zip>27203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Granfortuna, M.D.</last_name>
      <phone>336-832-1100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Core Health Cancer Center</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Granfortuna, M.D.</last_name>
      <phone>336-832-1100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Annie Penn Memorial Hospital</name>
      <address>
        <city>Reidsville</city>
        <state>North Carolina</state>
        <zip>27320</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Granfortuna, M.D.</last_name>
      <phone>336-832-1100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marion L. Shepard Cancer Center at Beaufort County Hospital</name>
      <address>
        <city>Washington</city>
        <state>North Carolina</state>
        <zip>27889</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John J. Inzerillo</last_name>
      <phone>252-975-4308</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanford Bismarck Medical Center</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Preston Steen, M.D.</last_name>
      <phone>701-234-6161</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanford Clinic North-Fargo</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Preston Steen, M.D.</last_name>
      <phone>701-234-6161</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanford Medical Center-Fargo</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Preston Steen, M.D.</last_name>
      <phone>701-234-6161</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Cooney, M.D.</last_name>
      <phone>216-844-7048</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anjali Advani, M.D.</last_name>
      <phone>216-445-9354</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of Southwest Oklahoma, LLC - Lawton</name>
      <address>
        <city>Lawton</city>
        <state>Oklahoma</state>
        <zip>73505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadim F. Nimeh, MD</last_name>
      <phone>580-536-2121</phone>
      <phone_ext>113</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sindhu Singh, M.D.</last_name>
      <phone>405-271-8777</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <zip>97330</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly McGregor, M.D.</last_name>
      <phone>541-768-4771</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Health Care - Portland</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nagendra Tirumali, MD</last_name>
      <phone>503-331-6500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Adams Cancer Center</name>
      <address>
        <city>Gettysburg</city>
        <state>Pennsylvania</state>
        <zip>17325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Tabatabai</last_name>
      <phone>717-741-8124</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>WellSpan Health-York Hospital</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Tabatabai, M.D.</last_name>
      <phone>717-741-9229</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanford Cancer Center Oncology Clinic</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miroslaw Mazurczak</last_name>
      <phone>605-328-8000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Swainey, M.D.</last_name>
      <phone>804-828-9723</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>PeaceHealth Saint Joseph Medical Center</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Goodman, M.D.</last_name>
      <phone>206-386-2122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harrison Health Partners Hematology and Oncology - Poulsbo</name>
      <address>
        <city>Poulsbo</city>
        <state>Washington</state>
        <zip>98370</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Goodman, M.D.</last_name>
      <phone>206-386-2122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Medical Center</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arvinder Bir, M.D.</last_name>
      <phone>304-528-4658</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Green Bay Oncology at Saint Vincent Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301-3526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony J. Jaslowski</last_name>
      <phone>610-402-2273</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Jaslowski, M.D.</last_name>
      <phone>920-884-3135</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony J. Jaslowski</last_name>
      <phone>610-402-2273</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holy Family Memorial Hospital</name>
      <address>
        <city>Manitowoc</city>
        <state>Wisconsin</state>
        <zip>54221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony J. Jaslowski</last_name>
      <phone>610-402-2273</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seth Fagbemi, M.D.</last_name>
      <phone>715-387-5426</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Hospital</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seth O. Fagbemi, MD</last_name>
      <phone>715-387-5426</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Green Bay Oncology - Oconto Falls</name>
      <address>
        <city>Oconto Falls</city>
        <state>Wisconsin</state>
        <zip>54154</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony J. Jaslowski</last_name>
      <phone>610-402-2273</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Nicholas Hospital</name>
      <address>
        <city>Sheboygan</city>
        <state>Wisconsin</state>
        <zip>53081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Jaslowski, M.D.</last_name>
      <phone>920-884-3135</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic at Saint Michael's Hospital</name>
      <address>
        <city>Stevens Point</city>
        <state>Wisconsin</state>
        <zip>54481</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seth O. Fagbemi, MD</last_name>
      <phone>715-387-5426</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Michael's Hospital Cancer Center</name>
      <address>
        <city>Stevens Point</city>
        <state>Wisconsin</state>
        <zip>54481</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seth O. Fagbemi, MD</last_name>
      <phone>715-387-5426</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Green Bay Oncology - Sturgeon Bay</name>
      <address>
        <city>Sturgeon Bay</city>
        <state>Wisconsin</state>
        <zip>54235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony J. Jaslowski</last_name>
      <phone>610-402-2273</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic - Weston Center</name>
      <address>
        <city>Weston</city>
        <state>Wisconsin</state>
        <zip>54476</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seth Fagbemi, M.D.</last_name>
      <phone>715-387-5426</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diagnostic and Treatment Center</name>
      <address>
        <city>Weston</city>
        <state>Wisconsin</state>
        <zip>54476</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seth Fagbemi, M.D.</last_name>
      <phone>715-387-5426</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>September 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
